Intrathecal Cell Therapy Administration Rate Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current intrathecal administration methods for treating neurodegenerative diseases are limited by adverse events such as back pain, lower limb pain, and cell clumping near the injection site, which reduce therapeutic efficacy due to inefficient cell distribution within the central nervous system.
Innovation Solution
A method involving the intrathecal administration of a therapeutic cell suspension at a controlled rate (0.1 to 2 ml/min) and concentration (1×10^5 to 2×10^7 cells/ml) during a lumbar puncture, with optional simultaneous drawing of cerebrospinal fluid, to ensure proper cell dispersion and attachment to the arachnoid and pia mater near the brain and spinal cord.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If intrathecal administration of therapeutic cells is performed at high dosage, then therapeutic efficacy is improved, but adverse events such as back pain, lower limb pain, and cell clumping increase
Solution Approach 1:
The patent applies parameter changes by optimizing the administration rate (0.1-2 ml/min) and cell concentration (1×10^5 to 2×10^7 cells/ml) to achieve high therapeutic dosage while minimizing adverse events. This resolves the contradiction by finding the optimal parameter range that balances efficacy and safety
Solution Approach 2:
The patent implements dynamics by using a controlled administration rate rather than fixed dosage delivery. The rate is adjusted during infusion (0.1-2 ml/min) to prevent cell clumping and reduce adverse events while maintaining high therapeutic cell dosage, allowing the system to adapt to real-time conditions
2Quantity of substance
If intrathecal administration is performed with high cell concentration, then therapeutic efficacy is improved, but cell clumping at the injection site occurs reducing distribution efficiency
Solution Approach 1:
The patent uses dynamic control of administration rate (0.1-2 ml/min) to prevent cell clumping while maintaining high cell concentration. The rate is adjusted based on real-time conditions to ensure proper cell dispersion throughout the cerebrospinal fluid, resolving the contradiction between high concentration and even distribution
Solution Approach 2:
The patent applies preliminary action by pre-diluting cells to appropriate concentrations (1×10^5 to 2×10^7 cells/ml) before administration and controlling the infusion rate from the start to prevent clumping. This preparatory concentration control ensures cells distribute properly before reaching the injection site
3Loss of time
If intrathecal administration is performed rapidly, then treatment time is reduced, but cell clumping and adverse events increase
Solution Approach 1:
The patent implements dynamic administration rate control (0.1-2 ml/min) that can be adjusted during the procedure. This allows the treatment to be completed in reasonable time while preventing cell clumping by slowing the rate when needed, resolving the contradiction between treatment speed and safety
Solution Approach 2:
The patent changes the administration rate parameter during the procedure (0.1-2 ml/min range) to optimize both treatment time and safety. The rate is modified based on patient response and cell distribution patterns, achieving efficient treatment without adverse events
Data Source
AI summary
The present invention provides methods of treating neurological diseases and disorders by intrathecal administration of cells, such as human stem cells, while the method provides a reduced rate of side effects associated with intrathecal administration.